A vaccine is being developed to protect people from a severe disease from the harmful effects of gluten.
Celiac disease is caused by an immune response to the gluten protein and is estimated to affect 1 in 70 New Zealanders and 1.4 percent of the global population.
The initial drug trial in New Zealand and Australia was successful, and researchers are now looking for volunteers in Auckland, Wellington and Havelock North for the next phase of testing.
Celiac New Zealand Managing Director Dana Alekander said the program identifies the way to desensitize the immune response of the body to gluten – similar to the exclusion of an allergic response.
"If successful, the vaccine will allow people with a condition to be exempted from the risk of being" gluten ", which would be especially useful when feeding from home or where safe gluten-free options are not available."
Researcher Dr. Dunedin Dr Bob Anderson is working on a drug, Nekvak2, in Biotechnology Massususet ImmusanT since 2012.
In 2014, first stage trials at sites, including Auckland, have taught researchers that the cell symptoms are caused by T cells that respond quickly to gluten peptide.
It has also been shown that the immune system may be overloaded to ignore the gluten peptide by repeated doses of Nekako2.
In the second phase of the study, efforts were made to show that regular doses of the drug can be protected against the effects of single-time gluten exposure in patients with cellulite who try to avoid gluten.
"Neko2's goal is not to replace the gluten-free diet, but to protect against acute symptoms due to unintentional exposure to gluten, which is a common problem with large patients often," he said.
But, Anderson hoped that someday someday somebody might go a step further and allow relaxation of eating restrictions in people with illness.
To learn more about participating in the studies of the 0800 STUDY in Auckland, 04 801 0002 in Wellington or 0800 141 559 in Havelock North.